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Objectives. The present trial investigated the efficacy and safety
of dalteparin in the prevention of arterial thromboembolism after
an acute anterior myocardial infarction (MI).
Background. Left ventricular (LV) thrombus formation is
associated with increased risk of arterial embolism in patients
with an acute MI. Thrombolytic and antiplatelet therapy do not
prevent thrombus formation.
Methods. A total of 776 patients were enrolled in a multicenter,
randomized, double-blind, placebo-controlled trial of subcutane-
ous dalteparin (150 IU/kg body weight every 12 h during the
hospital period). Thrombolytic therapy and aspirin were admin-
istered in 91.5% and 97.6% of patients, respectively. The primary
study end point was the composite of thrombus formation diag-
nosed by echocardiography and arterial embolism on day 9 6 2.
Results. Of 517 patients with echocardiographic recordings
available for end point analysis, thrombus formation or embolism,
or both, was found in 59 (21.9%) of 270 patients (59 with
thrombus, none with embolism) in the placebo group and 35
(14.2%) of 247 patients (34 with thrombus, 1 with embolism) in
the dalteparin group (p 5 0.03). The risk reduction of thrombus
formation associated with dalteparin treatment was 0.63 (95%
confidence interval 0.43 to 0.92, p 5 0.02). Analyses of all
randomized patients (388 in each group) revealed no significant
difference between the placebo and dalteparin groups with respect
to arterial embolism (6 vs. 5 patients), reinfarction (8 vs. 6
patients) and mortality rates (23 vs. 23 patients, p 5 NS for all).
Dalteparin was associated with an increased risk of hemorrhage:
major in 11 dalteparin group patients (2.9%) versus 1 placebo
group patient (0.3%, p 5 0.006); minor in 52 dalteparin group
patients (14.8%) versus 8 placebo group patients (1.8%, p <
0.001).
Conclusions. Dalteparin treatment significantly reduces LV
thrombus formation in acute anterior MI but is associated with
increased hemorrhagic risk.
(J Am Coll Cardiol 1997;30:962–9)
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Left ventricular (LV) thrombus formation frequently compli-
cates acute anterior myocardial infarction (MI), even in pa-
tients given thrombolytic therapy and aspirin (1–4). The
clinical relevance of thrombus is the association with an
increased risk of arterial embolism (5–7); thus, the prevention
of thrombus formation is important. Enhanced thrombin ac-
tivity, whether related to the acute event itself or to thrombo-
lytic therapy (8), plays a pivotal role in thrombus formation
and provides a rationale for the use of heparin in its preven-
tion. However, clinical trials have failed to demonstrate any
additional benefit of such treatment on morbidity or mortality
rates when given in conjunction with streptokinase and anti-
platelet agents (9,10).
New antithrombotic compounds are currently undergoing
clinical investigation. One group of these readily available
compounds for clinical use is the low molecular weight hepa-
rins (LMWHs). These compounds are derivatives of un-
fractionated heparin (UFH). However, the pharmacokinetic
properties of LMWHs differ from that of UFH. High dosage-
independent bioavailability and a longer half-life provide an
antithrombotic efficacy of subcutaneous LMWH that equals
intravenous UFH (11,12). The bioavailability of dalteparin, an
LMWH (molecular weight 5,000 daltons) derived from porcine
heparin through polymerization and ultrafiltration, is ;90%
(13). In comparison, the bioavailability of subcutaneous UFH
is highly variable and dose dependent. Only 20% of the drug is
absorbed at doses of 5,000 IU (14,15). The consequent inade-
quate antithrombotic response may explain the discouraging
clinical results with subcutaneous UFH (16–18). Furthermore,
LMWHs seem to bear less hemorrhagic risk than that observed
with UFH.
A recent study (19) demonstrated significant reduction in
morbidity and mortality, with low risk of hemorrhage, with
dalteparin in unstable angina pectoris. However, there are no
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reports from randomized trials on dalteparin in acute myocar-
dial infarction.
The objective of the present study was to investigate the
efficacy and safety of dalteparin in the prevention of LV
thrombus formation and arterial embolism after acute anterior
MI.
Methods
Study design and patients. The study was designed as a
prospective, randomized, double-blind, placebo-controlled,
multicenter trial with parallel groups. Three university hospi-
tals and 10 central and county hospitals in Norway participated
in patient recruitment. Informed consent was obtained from all
patients, and the study was otherwise also performed in
accordance with the Helsinki Declaration.
Thrombus formation may occur very early after an acute
MI. Thus, prompt administration of randomized treatment
before enzymatic verification of acute MI was encouraged.
Delay in study enrolment was omitted through randomization
on a 24-h/day basis and with few inclusion criteria: case history
and electrocardiographic (ECG) changes (i.e., Q waves or ST
segment elevation $1 mm in leads I and aVL or $2 mm in any
two or more contiguous leads of leads V1 through V6) sugges-
tive of an evolving anterior Q wave MI. These specific ECG
changes were chosen to rule out patients with infarct sites
other than anterior and those with a non–Q wave MI, both
associated with low risk of thrombus formation. Patients with
elevated enzyme levels but without the ECG changes were
treated according to local routines. Patients of either gender
and all ages were eligible for inclusion. Continued study drug
treatment required verification of a first anterior MI with a
peak aspartate aminotransferase (AST) value $100 U/liter or
creatine kinase (CK) twice normal levels or higher. Patients
with one or more of the following conditions were regarded as
ineligible: previous anterior MI, infarct site other than ante-
rior, time from onset of symptoms to start of study treatment
.15 h, ongoing treatment with or indication for heparin or
warfarin, systolic blood pressure .210 mm Hg, diastolic blood
pressure .115 mm Hg, cerebrovascular events within the
previous 2 months, known allergy to trial drug, peptic ulcer,
known bleeding disorders, serious liver or renal failure, preg-
nancy, neoplastic or concomitant life-threatening diseases,
alcohol abuse and simultaneous participation in other clinical
trials.
Study end points. The primary end point was the compos-
ite of LV thrombus formation diagnosed by echocardiography
on day 9 6 2 and arterial embolism. Secondary end points
encompassed reinfarction and total and cardiovascular mortal-
ity. Reinfarction was diagnosed by recurrent chest pain resis-
tant to glyceryltrinitrate associated with a significant rise in
AST and CK and new ST segment changes on the ECG. Safety
variables were minor and major hemorrhage (i.e., cerebrovas-
cular or any other bleeding that required transfusion or
surgical intervention), allergic reactions and thrombocytopenia
(i.e., platelet count #100 3 109/liter or reduction $50% from
prerandomization values). All randomized patients were fol-
lowed up for 3 months concerning efficacy variables. The
present report includes only in-hospital data.
LV thrombus on echocardiography. LV thrombus was de-
fined as an echodense mass within the ventricular cavity with 1)
a marked delineation toward the lumen and 2) a structural
texture different from the myocardium and that 3) could be
separated from the underlying endocardium by an endocardial
lining; 4) was visible throughout the entire cardiac cycle; and 5)
could be demonstrated in at least two different views. Throm-
bus shape was classified as protruberant when the free margin
toward the ventricular lumen was convex. Thrombus mobility
required demonstration of pendulations apart from those
mediated by myocardial contractions. LV wall motion was
graded from 0 to 3: 0 5 normal motion; 1 5 hypokinesia; 2 5
akinesia; 3 5 dyskinesia, including signs of LV aneurism.
Three different echocardiographs were used: Vingmed CFM
(models 700, 725, 750 and 800; all Vingmed Sound, Norway);
Irex Meridian (Johnson & Johnson); and Acuson 128 3 p/10
(Acuson). Multiple depth, gain and reject settings were used
for optimal visualization of intracavitary structures. Record-
ings from parasternal long- and short-axis, apical two- and
four-chamber and subcostal views were stored on separate
videocassettes using Panasonic AG 6200 (VHS PAL) and
Panasonic AG 7330 (SVHS PAL) video recorders. Before the
start of the study, the investigators, all experienced in echocar-
diography, attended a specially designed echocardiography
workshop to ensure homogenous examinations with optimal
quality. An end point classification committee with no knowl-
edge of the clinical data, including randomized treatment,
successively reviewed all echocardiographic recordings. The
local investigators continuously received reports on recording
quality from the committee. The committee members were
encouraged to make a joint conclusion after independent
review of the recordings. An external video audit committee
was responsible for final classification in cases of discrepancy.
Arterial embolism. A standardized clinical examination for
recognition of embolic events was performed repeatedly dur-
ing the hospital period. Ischemic stroke was defined as any focal
neurologic deficit of sudden onset that was observed by
persons other than the patient, lasted .30 min and cerebral
Abbreviations and Acronyms
AST 5 aspartate aminotransferase
CK 5 creatine kinase
ECG 5 electrocardiogram, electrocardiographic
GISSI-2 5 Gruppo Italiano per lo Studio della Sopravvivenza
nell’Infarto Miocardico II
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hemorrhage excluded by computed tomography. Suspected
arterial emboli to other regions were verified by angiography.
Study treatment. Dalteparin (Pharmacia, Sweden; 150 IU/kg
body weight every 12 h) was injected subcutaneously in the
abdominal region. This dosage was based on our own results in
a previous dose-finding study (20). Body weight was adjusted
to weight classes of 10 kg (i.e., 40 to 49, 50 to 59, 60 to 69), with
an upper limit of 100 kg. For safety reasons, the first study
injection was given 8 h after thrombolytic therapy. In patients
not receiving such therapy, study treatment was commenced
immediately after randomization. The scheduled treatment
period was 9 6 2 days.
Thrombolytic and concomitant antithrombotic therapy.
Intravenous streptokinase (1.5 3 106 IU/h) was administered
in patients with no contraindications and with symptoms #6 h
in duration. Soluble aspirin (300 mg) was given orally on
admission and 160 mg/day thereafter. No other antithrombotic
agents were allowed during the study period. At discharge
from the hospital, patients considered at high risk of throm-
boembolic events (i.e., thrombus or severe wall motion abnor-
malities) received warfarin; all others continued receiving
antiplatelet therapy.
Laboratory measurements. Analyses of plasma dalteparin
(Coatest LMW Heparin, Chromogenix, Sweden), thrombin–
antithrombin complex (Enzygnost TAT micro, Behring, Ger-
many) and D-dimer (Asserachrom D-Di, Stago, France) were
performed at the core laboratory in blood samples taken
before and 4 h after the study injection on the morning of
treatment days 2 and 7.
Statistical considerations. Patient data were recorded on
specially designed case record forms. Data processing was
performed by Pharmacia AB, Stockholm in cooperation with
the steering committee and clinical coordinator. All statistical
analyses were performed independently of the sponsor.
Sample size calculation. The major outcome measure was
the composite of LV thrombosis and arterial embolism at day
9 6 2 (mean 6 SD). Because of randomization before definite
verification of acute MI and a lower cutoff peak value for AST
of #100 U/liter, it was calculated that 30% of the randomized
patients would not meet the continuation criteria. Because of
technical reasons or early death, a further 10% were not
expected to have echocardiographic recordings available for
end point analyses. The end point incidence among those who
continued study participation was estimated to be 28% in the
placebo group. According to available published data, a 50%
reduction was estimated for sample size calculation. To reach
a power (1 2 beta) that equaled 90% at an alpha value of 0.05
(two-tailed) for detecting this reduction, 388 patients in each
group were needed.
Statistical methods. Analyses of LV thrombus formation
were performed in patients with available echocardiographic
recordings. However, all randomized patients were retained in
all other end point analyses. A two-sided exact Fisher-Irwin
test with a 5% significance level was applied for comparison of
specific events between the two patient groups. Logistic regres-
sion was used for simultaneous analyses of associations be-
tween background variables (including treatment) and efficacy
variables. Only statistically significant variables were retained
in the regression analyses. Results are presented as odds ratios
with 95% confidence intervals and p values.
Results
Patients. A total of 776 patients (388 in each treatment
group) with a suspected first acute anterior MI were random-
ized. Baseline characteristics of the two study groups were
similar (Table 1). Of all randomized patients, 91.5% received
streptokinase and 97.6% aspirin. The use of these drugs, as
well as other concomitant medical treatment, was equally
distributed between the treatment groups.
After randomization, 137 patients (17.7% [68 placebo, 69
dalteparin]) were ineligible for study continuation according to
protocol criteria. Of these 137 patients, 112 (81.8%), equally
distributed between the treatment groups, had an acute MI
and received streptokinase. However, the peak enzyme values
did not reach the lower cutoff limit for continuation. Discon-
tinuation from further study drug treatment occurred in 73
patients (9.4%) for reasons shown in Table 2. Thirty-six
patients (4.6% [19 placebo, 17 dalteparin]) died before echo-
cardiography. Thus, echocardiography was performed in 530
(68.3%) of 776 patients (277 placebo, 253 dalteparin). For
technical reasons, 7 (2.5%) of 277 echocardiographic record-
ings in the placebo group and 6 (2.4%) of 253 in the dalteparin
group were excluded from end point analyses. Thus, analysis of
LV thrombus formation was performed in 517 patients (270
placebo, 247 dalteparin) (Fig. 1). The difference in number of
patients not available for echocardiographic analyses was not
Table 1. Baseline Characteristics of Patients With Acute Anterior
Myocardial Infarction Randomized to Treatment With Dalteparin
or Placebo
Dalteparin
Group
(n 5 388)
Placebo
Group
(n 5 388)
Age (yr) 63.7 6 12.1 63.6 6 11.7
Men/women 281/107 288/100
Body weight (kg) 75.4 6 12.6 75.5 6 12.4
Killip class
I 347 349
II 27 28
III 4 2
IV 1 1
Missing 9 8
History of
Thromboembolism 12 5
Stroke 7 7
Hypertension 63 64
Congestive heart failure 6 5
Previous myocardial infarction 32 32
Time from onset of symptoms (h)
To thrombolytic therapy 4.3 6 2.2 4.8 6 5.5
To start of study treatment 12.5 6 2.4 12.3 6 3.5
Data presented are mean value 6 SD or number of patients.
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statistically significant (141 of 388 [placebo] vs. 118 of 388
[dalteparin], p 5 0.09). There was no difference in baseline
characteristics between treatment groups among patients avail-
able for analyses. All had a verified first acute anterior MI. No
patient received UFH during the study period, and there was
no crossover between treatment groups.
LV thrombus formation and arterial embolism. The com-
bined incidence of LV thrombus formation and arterial embo-
lism was 21.9% (59 of 270) in the placebo group and 14.2% (35
of 247) in the dalteparin group (p 5 0.030). LV thrombus
formation without embolism was found in 93 (18.0%) of 517
patients: 59 (21.9%) of 270 in the placebo group; 34 (13.8%) of
247 in the dalteparin group (p 5 0.022) (Table 3). There was
no significant difference in the prevalence of thrombus be-
tween the recruiting centers (p 5 0.31). During day 0 to 11,
arterial embolism occurred in 11 (1.4%) of 776 patients. Five
(1.3%) of 388 patients in the placebo group and 4 (1.0%) of
388 in the dalteparin group had a verified ischemic stroke. One
additional patient in the placebo group had a stroke, but this
event was not further classified. Peripheral arterial embolism
occurred in one patient given dalteparin.
Protruberant shape of the thrombus was found in 49 cases
(52.7%), and 7 (7.5%) were classified as mobile, with no
statistically significant difference between the treatment groups
(Table 3).
Irrespective of randomized treatment, the extent of LV wall
motion abnormalities was significantly associated with throm-
bus formation: grade 0 5 no thrombus; grade 1 5 3.6%
thrombosis; grade 2 5 24.3% thrombosis; grade 3 5 31.0%
thrombosis (p , 0.001 for linear association). The distribution
of LV wall motion abnormalities did not differ between
treatment groups.
Time from onset of symptoms to start of study treatment
was 12.6 6 2.4 h in patients with and 12.4 6 3.3 h in those
without thrombolytic therapy. (p 5 NS). Thrombus was diag-
nosed in 84 (17.5%) of 479 patients with compared with 9
(23.7%) of 38 without thrombolytic therapy (p 5 0.38).
Figure 1. Flowchart showing number of patients
randomized and selection for primary and secondary
end point and safety analyses.
Table 2. Reasons for Discontinuation Among 776 Patients With
Acute Myocardial Infarction Randomized to Treatment With
Dalteparin or Placebo
Discontinuation*
Dalteparin
Group
(n 5 388)
Placebo
Group
(n 5 388)
Hemorrhage† 33 3
Patient request 15 6
Indication for anticoagulation 6 9
Indication for invasive procedures 2 1
Administrative reasons 2 3
Other 4 2
Total 62 24
*A patient may have been discontinued for more than one reason. †See
Table 5 for details. Data presented are number of patients.
Table 3. Left Ventricular Thrombus Formation Among Patients
With Acute Anterior Myocardial Infarction Randomized to Receive
Dalteparin or Placebo
Dalteparin
Group
(n 5 388)
Placebo
Group
(n 5 388)
p
Value
Echocardiography 247 270
LV thrombosis 34 (13.8%) 59 (21.9%) 0.022
Protuberant 17 (50.0%) 32 (54.2%) NS
Mobile 1 (2.9%) 6 (10.2%) NS
Data presented are number (%) of patients. LV 5 left ventricular.
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However, after adjustment for peak AST value and gender
there was a trend toward an increased prevalence of thrombus
among patients not receiving thrombolytic therapy (p 5 0.08).
No other concomitant treatment (i.e., aspirin, beta-adrenergic
blocking agents, nitrates, diuretic drugs and angiotensin-
converting enzyme inhibitors) influenced thrombus formation.
Mean peak AST was higher in patients with (516 6 278
U/liter) than in those without thrombus (428 6 304 U/liter,
p 5 0.02). Furthermore, there was a nonsignificant trend
toward a higher mean peak CK value in patients with than in
those without LV thrombus (3,406 6 2,391 vs. 2,932 6 2,151
U/liter, respectively, p 5 0.09). LV thrombus developed in 16
(11.6%) of 138 women and 77 (20.3%) of 379 men (p 5 0.027).
After logistic regression analyses, randomized treatment,
peak AST value and gender remained significantly associated
with LV thrombus formation (Table 4).
Reinfarction and mortality. Reinfarction occurred in 14
(1.9%) of 776 patients during days 0 to 11: 8 (2.1%) of 388 in
the placebo group; 6 (1.6%) of 388 in the dalteparin group.
This difference was not statistically significant.
The total mortality rate during days 0 to 11 was 5.9%, with
no difference between the groups. The presumed cause of
death was cardiac related in all 23 patients in the placebo
group and in 21 of the patients in the dalteparin group. Two
patients in the dalteparin group died of intracranial hemor-
rhage.
Hemorrhage and other complications. Major hemorrhage
occurred in 12 patients (1.6%): 1 (0.3%) of 388 in the placebo
group; 11 (2.9%) of 388 in the dalteparin group (p 5 0.006).
Two fatal and one nonfatal cerebral hemorrhages occurred in
the dalteparin group and were verified by computed tomogra-
phy. In this treatment group, all patients were given thrombo-
lytic therapy, and 10 received aspirin. The event occurred
within 48 h after the start of treatment in six patients; further
clinical details are shown in Table 5. Minor hemorrhage
occurred in 52 of 388 dalteparin-treated patients and in 8 of
388 placebo-treated patients and were also significantly asso-
ciated with dalteparin treatment (p , 0.001) (Table 5). Two
minor bleeding events but no major event was related to
interventional procedures. Thrombocytopenia occurred in one
patient (0.3%) treated with dalteparin. No allergic reactions
were observed.
Laboratory measurements. The target range of plasma
dalteparin levels measured 4 h after the morning injection was
0.7 to 1.4 IU/ml on the basis of our previous results from a pilot
study (23). Blood samples taken on treatment day 7 from 225
patients in the dalteparin group revealed that 156 (69.3%) had
values within, 53 (23.6%) had values below, and 16 (7.1%)
values above the target range. Mean plasma concentration for
the whole group was 0.91 6 0.40 IU/ml. The plasma levels did
not differ significantly between patients with and without LV
thrombus (0.80 6 0.45 vs. 0.92 6 0.35 IU/ml, respectively, p 5
NS). The prevalence of thrombus among patients with plasma
levels #0.7 IU/ml was 21.6% compared with 11.1% among
those with plasma levels .0.7 IU/ml (p 5 NS). Analyses
revealed high plasma dalteparin levels (1.1 to 2.0 IU/ml) in
samples available from four patients with a major hemorrhage,
including two with a cerebral hemorrhage. There was no
significant difference in plasma dalteparin levels between pa-
tients with and without minor hemorrhage (0.96 6 0.51 vs.
0.91 6 0.37 IU/ml, respectively).
Thrombin–antithrombin complex and D-dimer levels mea-
sured in 174 patients did not differ between those with and
those without LV thrombus. Adjustment for randomized treat-
ment did not alter this result.
Discussion
The present trial assessed the potential benefits of subcu-
taneous dalteparin (150 IU/kg body weight every 12 h) in the
prevention of LV thrombus formation and arterial embolism
after acute anterior MI. The treatment groups were well
balanced with respect to baseline characteristics and prognos-
tically important factors, such as infarct size, degree of LV wall
motion abnormalities and time to treatment. The use of
Table 4. Odds Ratios (95% confidence intervals) of Left Ventricular
Thrombosis in Patients With Acute Anterior Myocardial Infarction
by Study Treatment, Peak Aspartate Aminotransferase Values
and Gender*
OR (95% CI)
p
Value
Assigned treatment
(dalteparin vs. placebo) 0.49 (0.29–0.83) 0.009
Peak AST value
(,215 vs. $215 U/liter) 0.12 (0.04–0.33) ,0.001
Gender (female vs. male) 0.50 (0.26–0.94) 0.033
*Data for all three variables were available for 419 patients. AST 5 aspartate
aminotransferase; CI 5 confidence interval; OR 5 odds ratio.
Table 5. Type of Hemorrhage According to Assigned Treatment
in Patients Given Dalteparin or Placebo for Acute
Myocardial Infarction
Hemorrhage
Dalteparin
Group
(n 5 388)
Placebo
Group
(n 5 388)
Major*
Cerebral 3 0
GI bleeding 3 1
Retroperitoneal 1 0
Epistaxis 2 0
SC hematoma 2 0
Total 11 1
Minor
SC (incl. injection site) 23 1
Urogenital 14 2
GI 8 3
Upper airway (incl. epistaxis) 5 2
Arterial puncture site 2 0
Total 52 8
*Defined as cerebrovascular bleeding or any bleeding requiring transfusion
or surgical intervention. Data presented are number of patients. GI 5 gastroin-
testinal; incl. 5 including; SC 5 subcutaneous.
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thrombolytic therapy, aspirin and other concomitant treatment
also did not differ between the groups. We found that dalte-
parin treatment was associated with a statistically significant
reduction in the composite end points of LV thrombus forma-
tion and arterial embolism (p 5 0.030).
LV thrombosis. The propensity of thrombus formation in
acute MI is influenced by several factors, such as infarct site
and size, LV dysfunction, including regional akinesia, and
clinical evidence of heart failure (see Danzig et al [21] for
review). Differences in these as well as other factors, such as
diagnostic techniques, time of examination and use of anti-
thrombotic treatment, cause substantial variation in the re-
ported frequency of thrombus from different series.
LV thrombosis occurred in 21.9% of patients in the placebo
group in the present trial. A similar frequency (26%) was
found in patients randomized to streptokinase in a compara-
ble, Gruppo Italiano per lo Studio della Sopravvivenza
nell’Infarto Miocardico II (GISSI-2)–connected study (4). In
our trial, weight-adjusted dalteparin treatment reduced throm-
bus formation by 37%, which is concordant with the effect of
fixed-dose subcutaneous UFH (12,500 IU every 12 h) in
thrombus prevention observed by Turpie et al. (22) (11% vs.
32%, p , 0.001). In contrast, this heparin treatment regimen
did not prevent thrombus formation in the GISSI-2–connected
trial (27% vs. 30%, p 5 NS). The concomitant use of throm-
bolytic therapy in the GISSI-2–connected study, as opposed to
the study by Turpie et al (22), may offer one explanation for the
lack of heparin effect in the former. Thrombolytic therapy is
associated with enhanced thrombin activity, and higher hepa-
rin dosages may therefore be needed to achieve adequate
anticoagulant effects when conjunctive heparin treatment is
given (23).
Furthermore, irrespective of thrombolysis, therapeutic lev-
els of anticoagulation are often not achieved with subcutane-
ous UFH due to slow release and limited capacity to saturate
heparin clearance sites. This limitation may become critical to
the treatment effect when given in conjunction with thrombo-
lytic therapy.
The beneficial effect of dalteparin in the present trial is
probably due to the better anticoagulation achieved with a
weight-adjusted dosage regimen and to the superior pharma-
cologic properties of LMWH versus UFH (e.g., better bioavail-
ability, avoidance of neutralization by platelet factor 4, less
binding to plasma proteins and endothelium) (24–26).
Arterial embolism, including stroke. The clinical relevance
of LV thrombosis is its relation to arterial embolism. In a
meta-analysis of 11 studies (7), the pooled odds ratio for
increased risk of embolization was 5.45 (95% confidence
interval 3.02 to 9.83) in patients with versus those without LV
thrombus. However, as with thrombus frequency, the reported
incidence of arterial embolism, including stroke, varies sub-
stantially in different series.
The low incidence of stroke in the present trial (1.2%) is
concordant with that observed in the GISSI-2–connected study
(0.5%). In contrast, earlier series (2,27,28), including that of
Turpie et al. (22), have reported higher stroke rates (1.5% to
10%). Again, differences in the use of thrombolytic and
antiplatelet therapy may be related to the variable event rates.
Such combined antithrombotic therapy seems to reduce the
embolic potential of a thrombus, although it apparently does
not prevent thrombus formation itself. Indeed, a significant
reduction in stroke rate was achieved with such combined
treatment in the Second International Study of Infarct Survival
(ISIS-2) trial (0.6% vs. 1.1%) (29).
Reperfusion by thrombolysis with improvement in left
ventricular contractility and blood flow, as well as direct effects
on the thrombus surface of thrombolytic agents and aspirin,
may influence thrombus morphology and thus reduce the risk
of embolism (21,30). The occurrence of thrombus mobility, a
morphologic characteristic associated with increased risk of
embolism, was notably lower in both the present trial (7.5%)
and the GISSI-2–connected study (2%) than that reported in
several series of patients not receiving thrombolytic and anti-
platelet therapy (;20%) (5,6,31–33). Dalteparin treatment did
not seem to influence thrombus mobility or shape in the
present trial.
An assumption of a direct relation between thrombus
presence and arterial embolism would suggest a lower embolic
event rate than that observed in the dalteparin group. How-
ever, a probability of 0.42 of achieving no difference between
the groups even if a true difference exists still makes it
conceivable that prevention of thrombus formation may influ-
ence the rate of arterial embolism in a larger population.
Reinfarction and death. The overall reinfarction rate dur-
ing days 0 to 11 was 1.9% (2.1% vs. 1.6%, p 5 NS). Although
consistent with the in-hospital event rate in patients random-
ized to receive streptokinase and aspirin in the ISIS-2 trial
(1.8%) (29), it is somewhat lower than that observed in other
large clinical trials (2.6% to 2.8%) (9,10). In the present trial,
the exclusion of patients at high risk for reinfarction (e.g.,
those with unstable angina or a non–Q wave myocardial
infarction [MI]) by per protocol criteria for study inclusion and
continuation may have influenced the event rate.
In one recent study (34), long-term treatment with LMWH
given in conjunction with thrombolytic therapy did reduce the
risk of reinfarction after acute MI. This reduced risk was also
found with long-term dalteparin treatment in patients with
unstable angina or a non–Q wave MI (19). Neither of these
studies have demonstrated any significant effect on mortality.
Hemorrhage. The overall rate of cerebral hemorrhage
(0.42%) is consistent with the Third International Study of
Infarct Survival (ISIS-3) results (10). All events occurred in the
dalteparin group. However, the low number of patients does
not permit any assessment of a potential relation to this
treatment.
Most patients with major hemorrhage in the dalteparin
group received streptokinase and aspirin, suggesting the need
for reduced dalteparin dosage. In the Fragmin During Insta-
bility in Coronary Artery Disease (FRISC) trial (19), major
hemorrhage was reduced from 6.3% to 0.8% by lowering the
dalteparin dosage from 150 to 120 IU/kg body weight twice
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daily. However, thrombolytic therapy was not used because
these patients had unstable angina pectoris or a non–Q wave
MI.
Compared with the 2.9% incidence of major hemorrhage
associated with dalteparin treatment in the present trial, this
complication seems to occur in ;4% of patients treated with
intravenous UFH. Dalteparin, even at a dosage of 150 IU/kg
body weight twice daily, may thus be associated with lower
hemorrhagic risk.
Study limitations. Early randomization, before establish-
ment of a definite diagnosis of acute MI, has the risk of
including patients with either aborted or small infarctions.
Such patients are at low risk of thromboembolic complications.
Thus, the study protocol included a lower cutoff limit of peak
AST #100 U/liter in its continuation criteria. The sample size
calculation included an estimate that 40% of randomized
patients would not have available echocardiographic record-
ings because of failure to meet the continuation criteria or for
other reasons (e.g., death, withdrawal, technical). The actual
rate of patients without available recordings was 33.4%. How-
ever, although unequal in the two groups, the rates did not
differ significantly. Furthermore, except for end points that
included LV thrombosis, all statistical analyses were based on
intention to treat, thus retaining all 776 randomized patients.
Patients with LV thrombosis remain at risk for embolic
events beyond the acute phase. A study period of 11 days, as in
the present trial, may have contributed to the low rate of
arterial embolism. These conditions, together with the unclear
clinical significance of LV thrombi without embolism, restrict
the “risk–benefit” assessment of dalteparin treatment.
An observed risk reduction lower than that calculated in the
sample size estimation may imply a weakened statistical signif-
icance. However, in the present study the observed risk
reduction of 37%, as opposed to a calculated reduction of
50%, was still statistically significant. Thus, the difference
between the calculated and observed risk reduction should not
affect the interpretation of the results of the present study.
Conclusions. Dalteparin (150 IU/kg body weight twice
daily) is associated with a significant reduction in LV thrombus
formation in patients with an acute anterior MI, even when
streptokinase and aspirin are routinely given. Whereas the
results of randomized trials with UFH (35) do not appear to
justify the routine addition of UFH to aspirin, conjunctive
dalteparin treatment may thus improve clinical outcome of
patients with acute MI. However, it remains to be determined
whether the benefit observed with dalteparin in the present
trial could be extended to include the prevention of clinically
important events in a larger patient population.
Dalteparin treatment carries an increased risk of hemor-
rhage. However, this risk appears to be lower than that
observed with UFH, and a presumed better tolerance of a
reduced dalteparin dosage must be weighed against a possible
loss in clinical benefit.
Further investigations should aim at identification of pa-
tients at particularly high risk of both thromboembolic and
hemorrhagic complications.
We are indebted to the many co-workers (see Appendix) and, above all, patients
for their participation in this trial.
Appendix
The FRAMI Study Group
Steering committee. Chair: Jon Dale, MD, PhD; Co-Chair: Ulrich Abildgaard,
MD, PhD; Members: Terje Pedersen, MD, PhD, Frederic Kontny, MD, Anders
Nesvold, MD. Study coordinator: Frederic Kontny, MD. Safety monitoring
committee: Bernt Ly, MD, PhD, Terje Andersson, MD. Participating centers,
investigators and study nurses: Aker sykehus, Oslo: Frederic Kontny, Nina
Kristiansen. Akershus sentralsykehus, Nordbyhagen: Arfinn Rollag, Frøydis
Sjølyst, Tom Finn Olsen. Askim sykehus, Askim: Trond Fløgstad, Marit Buseng-
dal. Diakonissehjemmets sykehus, Bergen: Rune Fanebust, Elin Magnussen.
Haugesund sykehus, Haugesund: Kjell Waage, Eva Viland. Hedmark sentralsyke-
hus, Elverum: Hall Schartum-Hansen, Trude Grønvold, Anne G. Moe.
Kongsvinger sykehus, Kongsvinger: Erik Anker, Kari Glasø. Moss sykehus, Moss:
Per Lem, Jorunn Gregersen. Møre og Romsdal sentralsykehus, Ålesund: Torstein
Morstøl, Kirsti Sørdahl. Orkdal Sanitetsforenings sykehus, Orkanger: Arve Troms-
dal, Tore G. Salvesen, Oddny Rian. Regionsykehuset, Trondheim: Lars Hegrenæs,
Andrea Stoum, Inger Lundhaug. Telemark sentralsykehus, Porsgrunn: Dag Tor-
vik, Helge Flaten. Telemark sentralsykehus, Skien: Kenneth Knutsen, Randi M.
Johnson. Pharmacia study coordinator: Per Blom MD, PhD. Data Monitoring
and entry center (Pharmacia): Svend Undeland, Carin Fellenius, Claes Go¨ran
Broba¨ck, Grete Handeland, Tor Seim, Kerstin Wicklund, Gudrun Ekman. Data
analyses (Medstat Research, Lillestrøm): Leiv Sandvik, PhD. End point classi-
fication committee: Jon Dale, MD, PhD, Frederic Kontny, MD. External video
audit committee: Jan Erik Nordrehaug, MD, PhD, Karl Arne Johannessen, MD,
PhD. Core laboratory (Haematological Research Laboratory, Aker University
Hospital): Ulrich Abildgaard, MD, PhD, Mette Lie Larsen, Ellen Røkås.
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